<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03142542</url>
  </required_header>
  <id_info>
    <org_study_id>2017-02-112</org_study_id>
    <nct_id>NCT03142542</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Udenafil in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy</brief_title>
  <acronym>DA8159_EDP_IIT</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial to Evaluate the Efficacy and Safety of Udenafil Dosed Once a Day in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of Udenafil dosed once a day in patients with&#xD;
      erectile dysfunction after bilateral nerve-sparing radical prostatectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">May 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients who has IIEF-EF score ≥22</measure>
    <time_frame>at 32 weeks</time_frame>
    <description>The IIEF-EF score is International Index of Erectile Function - Erectile Function. The Questionaire is composed of 6 questions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety evaulation: Occurrence of any adverse events</measure>
    <time_frame>for 32 weeks</time_frame>
    <description>The AE is evaluated for grade, intensity, relationship by protocol definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation: Systolic and diastolic blood pressure</measure>
    <time_frame>for 32 weeks</time_frame>
    <description>by Physical exam, mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation: 12-lead ECG</measure>
    <time_frame>for 32 weeks</time_frame>
    <description>ECG test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation: Number of Participants With Abnormal Laboratory Values</measure>
    <time_frame>for 32 weeks</time_frame>
    <description>Blood and urine test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation:pulse rate</measure>
    <time_frame>for 32 weeks</time_frame>
    <description>by Physical exam, beats per minute</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Prostate Cancer With Radical Prostatectomy</condition>
  <arm_group>
    <arm_group_label>Udenafil 75mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Udenafil 75mg by mouth, once daily, for 32 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: placebo by mouth, once daily, for 32 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZYDENA TAB.75mg(Udenafil 75mg)</intervention_name>
    <description>ZYDENA TAB.75mg(Udenafil 75mg): by mouth, Once daily, for 32 weeks</description>
    <arm_group_label>Udenafil 75mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo Oral Tablet: by mouth, Once daily, for 32 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male aged 20 or over 20 years and not more than 70 years who underwent bilateral&#xD;
             nerve-sparing radical prostatectomy due to prostate cancer without metastasis&#xD;
&#xD;
          -  IIEF-EF score ≥22 at 1-8 weeks before bilateral nerve-sparing radical prostatectomy,&#xD;
             and IIEF-EF ≤16 at screening visit&#xD;
&#xD;
          -  Presence of sexual partner from 8 weeks before bilateral nerve-sparing radical&#xD;
             prostatectomy, and had planned to keep it during the trial&#xD;
&#xD;
          -  Agreed not to use any other erectile dysfunction medication (including both generic&#xD;
             and specialty medicines) and other erectile dysfunction therapies during the trial&#xD;
             period.&#xD;
&#xD;
          -  Patient agrees to voluntary participation and follow the instructions carefully, after&#xD;
             fully hearing and understanding the details of this clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who needs additional treatment in addition to bilateral nerve- sparing radical&#xD;
             prostatectomy&#xD;
&#xD;
          -  Use Inhibitors of PDE-5 (Viagra®, Levitra®, Cialis®, Zydena®, Yaila®, Mvix® and&#xD;
             Generic Medicines) or autologous injections of vasodilators or other erectile&#xD;
             dysfunction therapies for erectile dysfunction within the first 8 weeks of bilateral&#xD;
             nerve-sparing radical prostatectomy&#xD;
&#xD;
          -  If there is an uncontrolled diabetes (HbA1C&gt; 12%) at Visit 1&#xD;
&#xD;
          -  If there is proliferative diabetic retinopathy at Visit 1&#xD;
&#xD;
          -  If there is a history of CABG surgery, stroke, unstable angina, myocardial infarction,&#xD;
             life-threatening arrhythmia, or heart failure within 6 months before the screening&#xD;
             visit&#xD;
&#xD;
          -  History of spinal cord injury, non nerve-sparing radical prostatectomy or radical&#xD;
             pelvic surgery&#xD;
&#xD;
          -  Hypotension below 90 / 50mmHg or uncontrolled hypertension above 170 / 100mmHg&#xD;
&#xD;
          -  Penis anatomic abnormalities (severe penile fibrosis, Peyronie's disease, etc.)&#xD;
&#xD;
          -  Presence of serious disability such as malignant tumor, lung, blood, endocrine system&#xD;
             in Visit 1&#xD;
&#xD;
          -  Patient who have active hepatitis B or C or who are infected with HIV virus&#xD;
&#xD;
          -  Patient who have genetic problems such as galactose intolerance, Lapp lactose&#xD;
             dehydrogenase deficiency, glucose-galactose uptake disorder&#xD;
&#xD;
          -  Patient who have hyperprolactinemia or hypothyroidism&#xD;
&#xD;
               -  Serum AST and ALT are three times higher than normal upper limit&#xD;
&#xD;
               -  Serum Creatinine ≥ 2.5 mg / dl&#xD;
&#xD;
          -  Patient who have retinitis pigmentosa&#xD;
&#xD;
          -  Patient who have blood disease (sickle cell disease, multiple myeloma, leukemia) or&#xD;
             bleeding disorder that can cause priapism&#xD;
&#xD;
          -  Patient with congenital QT prolongation syndrome or those taking a drug that increases&#xD;
             QT interval&#xD;
&#xD;
          -  If the examiner considers that he / she is not suitable for participation in clinical&#xD;
             trials, such as mental disorder or persistent abuse of medication&#xD;
&#xD;
          -  Patient who is taking Nitrate / Nitric oxide (NO) donor (Nitroglycerin, Sodium&#xD;
             nitroprusside, Isosorbide mononitrate / dinitrate, Amyl nitrate / nitrite, etc.)&#xD;
&#xD;
          -  Patient who is taking Guanylate Cyclase stimulator (such as Riociguat)&#xD;
&#xD;
          -  Patient who is taking warfarin&#xD;
&#xD;
          -  Patient who is taking medications or foods that affect CYP3A4 metabolism&#xD;
&#xD;
               -  Metabolic inhibitors: Antibacterials (Erythromycin, etc.), Antifungals&#xD;
                  (Itraconazole, etc.), Antivirals (Ritonavir, Saquinavir, Amprenavir, Indinavir,&#xD;
                  Nelfinavir, etc.), H2 receptor antagonist (Cimetidine, etc), or grapefruit juice&#xD;
&#xD;
               -  Metabolic inducers: Dexamethasone, Rifampicin, Antipyretics (Phenytoin,&#xD;
                  Phenobarbital, Carbamazepine, etc.)&#xD;
&#xD;
          -  Patient who is taking androgens (Testosterone, etc.) or anti-androgens (5α-reductase&#xD;
             inhibitors such as Finasteride, Dutasteride and anti- androgen hormones such as&#xD;
             Flutamide and Bicalutamide)&#xD;
&#xD;
          -  Patient who is taking Trazodone&#xD;
&#xD;
          -  Patient who received other clinical trial medications (including placebo) within 4&#xD;
             weeks before the screening visit&#xD;
&#xD;
          -  History of hypersensitivity reactions to PDE-5 inhibitors (Viagra®, Levitra®, Cialis®,&#xD;
             Zydena®, Yaila®, Mvix® and each Generic drug)&#xD;
&#xD;
          -  Patient who did not respond to PDE-5 inhibitors (Viagra®, Levitra®, Cialis®, Zydena®,&#xD;
             Yaila®, Mvix® and each Generic drug)&#xD;
&#xD;
          -  Patient who has hypoactive sexual desire&#xD;
&#xD;
          -  If the examiner judges that it is not suitable for participation in this trial&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SeongSoo Jeon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SeongSoo Jeon, PhD</last_name>
    <phone>82-2-3410-3555</phone>
    <email>seongsoo.jeon@samsung.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HongMo An, Master</last_name>
    <phone>82-2-3410-6853</phone>
    <email>ahm0125.an@samsung.com</email>
  </overall_contact_backup>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>April 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2017</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Seong Soo Jeon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Udenafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

